Results 121 to 130 of about 18,044 (238)

Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune‐related adverse events, highlighting their impact on surgical timing, postoperative recovery, and ...
Shuang Li, Jianguo Wang, Yingjie Liu, Wenwu Cai, Weichang Zhang, Shengyun Li, Yunjian Zhang   +6 more
wiley   +1 more source

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy‐Induced Neutropenia in Patients With Diffuse Large B‐Cell Lymphoma: A Multicenter Pilot Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang, He Li, Qiaochu Lin, Yong Guo, Hongbing Ma, Bing Xiang, Chenlu Yang, Kai Shen, Chunlan Zhang, Kun Yang, Chunrong Ma, Hong Zhai, Jin Wei, Yan Zuo, Jie Zhou, Ting Niu   +15 more
wiley   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1156-1159, May 2026.
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli, Katarina V. Ilic, Rob C. van Wijk, Mohamed Elmeliegy, Jatinder Kaur Mukker, Aarti Sawant‐Basak, Tao Long, Juyao Dong, Noha Rayad, Tao Zhang, on behalf of the DRO Network   +13 more
wiley   +1 more source

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare

Pharmaceuticals
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Filipa Mascarenhas-Melo, Mariana Diaz, Maria Beatriz S. Gonçalves, Pedro Vieira, Victoria Bell, Sofia Viana, Sara Nunes, Ana Cláudia Paiva-Santos, Francisco Veiga   +8 more
doaj   +1 more source

The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy . [PDF]

, 2017
Background and aim: The monitoring of appropriateness and costs of biological therapy in Inflammatory bowel disease (IBD) is a relevant need. We aimed to evaluate appropriateness, efficacy and safety of biological therapy in IBD in Sicily through a web ...
Accomando S., Belluardo N., Calandruccio G., Cappello M., Carroccio A., Citrano M., Cottone M., Di Mitri R., Fries W., Genova S., Inserra G., Macaluso F. S., Magnano A., Magrì G., Orlando A., Orlando R., Pellegrino S., Privitera A. C., Renna S., Rizzuto G., Romano C., Scarpulla G., Siringo S., Trovatello N., Vassallo R., Ventimiglia M., Vinci E.   +26 more
core   +1 more source

Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1216-1222, May 2026.
Pharmacometrics (PMX) in Africa has transitioned from foundational capacity‐building to job creation, scientific leadership, regulatory influence, and health innovation. To accelerate this progress, the 2025 Pharmacometrics Africa Conference (PMXAC‐2025) convened key stakeholders to consolidate the continental PMX community, review progress in local ...
Babatunde Ayodeji Adeagbo, Innocent Gerald Asiimwe, Linda Chaba, Aida N. Kawuma, Francis Williams Ojara, Ochuko Maureen Orherhe, Simon Peter Asiimwe, Veshni Pillay‐Fuentes Lorente, Sharon Sawe, Cassius M. Phogole, Catriona Waitt, Samer Mouksassi, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

Growth in Paediatric Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Impaired linear growth is a common, clinically meaningful complication of paediatric inflammatory bowel disease (IBD), particularly Crohn's disease, arising from the combination of chronic intestinal inflammation, undernutrition, dysfunction of the growth hormone–insulin‐like growth factor‐1 axis, and iatrogenic effects such as glucocorticoid ...
Firas Rinawi, Séamus Hussey, Eileen Crowley, Dror S. Shouval, Iva Hojsak   +4 more
wiley   +1 more source

Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Objective: Global healthcare costs continue to rise annually, and this is a major challenge given the scarce resources and growing prices of innovative drugs. An interesting alternative for reducing costs is the use of biosimilars.
Maria Luísa BRODT-LEMES, Diana Saiara BRUSCATO, Douglas Silva MADRUGA, Joice SMANIOTTO, Julia Roberta SAGGIORATO-LUBIAN, Letícia Tramontina DE-VILLA, Suhélen CAON, Thamyrys Bessa SILVA   +7 more
doaj   +1 more source